Target Price | $8.16 |
Price | $1.24 |
Potential |
558.07%
register free of charge
|
Number of Estimates | 9 |
9 Analysts have issued a price target Gossamer Bio, Inc. 2026 .
The average Gossamer Bio, Inc. target price is $8.16.
This is
558.07%
register free of charge
$15.75
1,170.16%
register free of charge
$1.26
1.81%
register free of charge
|
|
A rating was issued by 15 analysts: 12 Analysts recommend Gossamer Bio, Inc. to buy, 3 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Gossamer Bio, Inc. stock has an average upside potential 2026 of
558.07%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 114.70 | 29.20 |
74.55% | ||
EBITDA Margin | -51.52% | -501.21% |
872.90% | ||
Net Margin | -49.29% | -536.82% |
989.21% |
10 Analysts have issued a sales forecast Gossamer Bio, Inc. 2025 . The average Gossamer Bio, Inc. sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Gossamer Bio, Inc. EBITDA forecast 2025. The average Gossamer Bio, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
11 Gossamer Bio, Inc. Analysts have issued a net profit forecast 2025. The average Gossamer Bio, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -0.25 | -0.69 |
78.81% | 176.00% | |
P/E | negative | |
EV/Sales | 7.59 |
11 Analysts have issued a Gossamer Bio, Inc. forecast for earnings per share. The average Gossamer Bio, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Gossamer Bio, Inc....
Analyst | Rating | Action | Date |
---|---|---|---|
Goldman Sachs |
Locked
➜
Locked
|
Locked | May 16 2025 |
Wedbush |
Locked
➜
Locked
|
Locked | May 16 2025 |
Goldman Sachs |
Locked
➜
Locked
|
Locked | Apr 17 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 18 2025 |
Wedbush |
Locked
➜
Locked
|
Locked | Mar 14 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jan 30 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Nov 11 2024 |
Analyst Rating | Date |
---|---|
Locked
Goldman Sachs:
Locked
➜
Locked
|
May 16 2025 |
Locked
Wedbush:
Locked
➜
Locked
|
May 16 2025 |
Locked
Goldman Sachs:
Locked
➜
Locked
|
Apr 17 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 18 2025 |
Locked
Wedbush:
Locked
➜
Locked
|
Mar 14 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jan 30 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Nov 11 2024 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.